Skip to main content

Market Overview

Moderna's Stock Valuation Goes From 'Unreasonable To Ridiculous': Analyst

Share:
Moderna's Stock Valuation Goes From 'Unreasonable To Ridiculous': Analyst

Moderna, Inc. (NASDAQ: MRNA) shares have rallied since the start of July, rendering the valuation unattractive and "ridiculous," according to a BofA Securities analyst. 

The Moderna Analyst: Geoff Meacham maintained an Underperform rating on Moderna with a $115 price target.

The Moderna Thesis: At a roughly $200-billion market value, Moderna has eclipsed pharma industry veterans Merck & Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY) and Amgen, Inc. (NASDAQ: AMGN), Meacham said in a Tuesday note. 

The latter three companies, the analyst said, are therapeutics businesses with proven long-term track records and deep/ diversified late-stage pipelines. 

Related Link: The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

To justify Moderna's $200-billion valuation, the company needs to sell 1.5 billion doses of COVID-19 vaccine each year from 2022 through 2038, and its entire pipeline must succeed with aggregate peak sales of $30 billion, Meacham said.

"These assumptions are, in our view, impossible to justify," the analyst said.

A $485 fair value for the share would require cumulative COVID-19 vaccine sales of $340 billion through 2038, contributing $280 per share, and a pipeline value of $170 per share, which represents a 100% success rate for four Phase 2 programs, 10 Phase 1 programs and 8 preclinical programs, he said. 

Feedback from infectious disease experts, Meacham said, provides support for a skeptical longer-term view of COVID-19 vaccines, even with the emergence of variants like delta.

MRNA Price Action: At last check, Moderna shares were down 5.69% to $456.88. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

How to Buy Moderna (NASDAQ: MRNA) Stock 

Latest Ratings for MRNA

DateFirmActionFromTo
Mar 2022Deutsche BankMaintainsHold
Feb 2022Morgan StanleyMaintainsEqual-Weight
Feb 2022SVB LeerinkMaintainsUnderperform

View More Analyst Ratings for MRNA

View the Latest Analyst Ratings

 

Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Health Care Price Target Reiteration Top Stories Analyst Ratings Movers Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com